The United States National Institutes of Health (NIH) signed a deal today with the World Health Organization’s COVID-19 Technology Access Pool (C-TAP) and the Medicines Patent Pool (MPP) that allows manufacturers greater access to key COVID-19 technologies owned by NIH. The licensing agreement offers 11 technologies under transparent, global and non-exclusive licenses. They include “the stabilized spike protein used in currently available COVID-19 vaccines, research tools for vaccine, therapeutic and diagnostic development as well as early-stage vaccine candidates and diagnostics.”
Recent Posts
- Straight to the Prompt: IP Lawyers Must Develop AI Skills NOW
- This Week in Washington IP: Evaluating the U.S.’s Role in IP Leadership, CHIPS Act Successes and Semiconductor Production, and the White House Policy on AI
- Laser Lessons: Has the Supreme Court Undermined Pioneering Laser Patents?
- Other Barks and Bites for Friday, December 1: Senators Discuss AI and Intellectual Property; EU Report Finds 86 Million Fake Items Were Detained Last Year; USPTO Releases New China IP Rights Toolkit
- IP Goes Pop! – Lessons From Movies About Innovators